Monopar Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Loss per Share (Tables)

6 Months Ended

Jun. 30, 2024

	Three Months Ended June 30,						Six Months Ended June 30,
(in thousands, except for net loss per share)	*2024*			*2023*			*2024*			*2023*
Numerator:
Net loss	$	(1,715	)	$	(2,200	)	$	(3,357	)	$	(4,635	)

Denominator:
Weighted-average common shares outstanding, basic and diluted		17,515			13,420			16,747			13,264

Net loss per common share, basic and diluted	$	(0.10	)	$	(0.16	)	$	(0.20	)	$	(0.35	)

Anti-dilutive potential common stock equivalents excluded from the calculation of net loss per share
Stock options to purchase common stock		2,104			2,114			2,104			2,114
Unvested restricted stock units		349			526			349			526